NCT02623868 - Study to Assess PK/PD Character, Safety/Tolerability of CKD-519 New Formulation in Healthy Male Subject. | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 31, 2015

Primary Completion Date

December 31, 2015

Study Completion Date

December 31, 2015

Conditions

Dyslipidemia

Interventions

DRUG

CKD-519 50mg 2Tabs.

after taking Standard meal, CKD-519 50mg 2Tabs. administration.

DRUG

CKD-519 100mg 1Tab.

after taking Standard meal, CKD-519 100mg 1Tab. administration.

DRUG

CKD-519 100mg 1Cap.

after taking Standard meal, CKD-519 100mg 1Cap. administration.

Trial Locations (1)

Korea university medical center, Seoul